What is it about?
Cancer vaccines need to deliver tumor antigens and help the immune system mount an effective response. We investigated a platform combining biodegradable poly-L-lactic acid (PLLA) microfibers, zinc oxide (ZnO) nanowires, and carcinoembryonic antigen (CEA), a tumor-associated protein. The vaccine activated dendritic cells, which help initiate targeted immunity, and stimulated both antibody and T-cell responses. It supported balanced Th1/Th2-associated immunity, engaging complementary immune defenses. In a mouse model, vaccination before tumor challenge reduced tumor growth by approximately 65–70% compared with PBS controls during the observation period. Vaccinated tumor-bearing mice also showed increased CD8 T cells in the spleen and natural killer cells within tumors. These findings connect systemic immune responses with changes in the tumor immune environment.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
This study brings together material design, antigen delivery, antibody responses, cellular immunity, and changes within the tumor immune environment. It shows why cancer-vaccine platforms should be evaluated across multiple aspects of immunity. Our earlier research demonstrated therapeutic effects against established tumors in mice. This study extends that work to vaccination before tumor exposure, providing a broader understanding of the PLLA–ZnO platform. The findings offer a foundation for researchers developing cancer nanovaccines and immune-stimulating delivery systems. Further studies are needed to establish durable immune memory, effectiveness across other tumor models, and suitability for human use.
Perspectives
In 2017, I asked on ResearchGate, "How does ZnO support the immune system in vaccines and cancer immunotherapy?" That question reflects a continuing interest in understanding how nanomaterials influence biological responses. Our research journey progressed from intracellular biomolecule delivery to therapeutic cancer vaccination in our 2019 nanoscale study. This new work expands the picture by examining antibody and T-cell responses, prophylactic protection, and the immune environment within tumors. For me, the next important questions concern how long protection lasts and which immune populations are essential to it. I welcome discussion from researchers working on antigen delivery, vaccine adjuvants, and tumor immunology. I am deeply grateful to my mentors, Professor Nam-Hyuk Cho and Professor Young Keun Kim, and to all collaborators and co-authors who contributed to this research journey.
Dr. Prashant Sharma
Read the Original
This page is a summary of: PLLA–ZnO nanowire nano-vaccine orchestrates balanced Th1/Th2 immunity and confers prophylactic antitumor protection, Cancer Nanotechnology, September 2026, Springer Science + Business Media,
DOI: 10.1186/s12645-026-00429-3.
You can read the full text:
Contributors
The following have contributed to this page
